Vitable Health

vitablehealth.com →

+53%

est. 2Y upside i

HealthcareSeries A

Affordable care via ICHRA and primary care with visits, meds, labs…

Rank

#1604

Sector

Healthcare

Est. Liquidity

~5Y

Data Quality

Data: Low

Vitable Health is a capital-efficient outlier — $28.6M in revenue against only $27.4M in total funding is rare for a Series A healthcare startup and suggests credible unit economics — but the complete absence of a disclosed valuation and YoY growth rate makes it impossible to objectively price the equity today.

Last updated: May 14, 2026

Bull (15%)+250%

Vitable's ICHRA expansion via Liferaft, GLP-1 services, and the DirectShifts partnership accelerate revenue to ~$60M by mid-2028, enabling a Series B at ~$420M (7x revenue). From an estimated ~$120M current baseline valuation, common equity holders realize approximately 250% upside before incremental dilution.

Base (55%)+67%

Steady Liferaft integration and moderate SMB expansion lift revenue to ~$42M by mid-2028, supporting a Series B at ~$200M (4.8x revenue). From the ~$120M estimated current valuation, common stockholders see roughly 67% upside, materially reduced by one additional dilutive round.

Bear (30%)-70%

Liferaft integration complexity drains management bandwidth, growth stalls below $35M revenue, and a tightened fundraising environment forces a bridge or down round below $60M. After the $27.4M preference stack is satisfied, common stockholders face losses of 70% or more.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

23%

$27.4M in total liquidation preferences against an estimated ~$120M valuation represents a ~23% preference stack, meaning the first $27.4M of any exit proceeds flow entirely to preferred holders before common stockholders receive a dollar.

Dilution Risk

high

As a Series A company that will almost certainly require at least one additional major financing round before any liquidity event, current equity grants face an estimated 25-45% incremental dilution.

Secondary Liquidity

none

No secondary market activity has been identified for Vitable Health; all equity grants should be treated as fully illiquid for a minimum of 4-6 years from today.

View all 9 open roles at Vitable Health →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Vitable Health's data — designed to show you've done your homework.

  • 1

    “How does the Liferaft ICHRA acquisition change your go-to-market, and what is the targeted revenue mix between direct primary care subscriptions and ICHRA administration over the next 24 months?”

  • 2

    “What is your current monthly net revenue retention rate, and how does employer-level churn compare to individual member churn across your SMB cohorts?”

  • 3

    “What is the current 409A valuation per share, what was full-year ARR growth in the most recent fiscal year, and when are you targeting a Series B raise?”

Community

Valuation Sentiment

Our model estimates +53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.